Northern Ireland-based Galen Holdings said clinical research study results presented at the annual meeting of the North American Menopause Society last Friday were encouraging.
The results were for its first intravaginal ring designed to provide long-term estrogen treatment for menopausal-associated symptoms in women, including hot flushes, night sweats, and local urogenital problems.
There are no therapies commercially available to treat these symptoms.
The research reported over 90 per cent of the women who used the therapy in the study stated they would choose this form of estrogen therapy if it were available.
Last month, Galen Holdings launched the therapy in Britain, its first market, under the brand name Menoring.
Galen is an integrated specialty pharmaceutical company based in Craigavon, Northern Ireland and Rockaway, New Jersey, in the US.